SCHEMBL3673873

SCHEMBL3673873

COCOc1ccc(C=C2SC(=O)NC2=O)cc1OCOC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.71
PIM1 P11309 3/20 0.69
PIM3 Q86V86 3/20 0.69
PIM2 Q9P1W9 3/20 0.69
PDE4B Q07343 2/20 0.69
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
GSK3B P49841 2/20 0.61
CDC7 O00311 1/20 0.61
DAPK3 O43293 1/20 0.61
DYRK3 O43781 1/20 0.61
MAP4K4 O95819 1/20 0.61
PHKG2 P15735 1/20 0.61
RPS6KB1 P23443 1/20 0.61
CSNK1D P48730 1/20 0.61
CLK2 P49760 1/20 0.61
GSK3A P49840 1/20 0.61
NEK4 P51957 1/20 0.61
CSNK2A1 P68400 1/20 0.61
CSNK1G2 P78368 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3673866 1.00 IGF1R (0.71) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL13572430 1.00 IGF1R (0.71) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL3672069 0.83 PIM1 (0.54) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL3672071 0.83 PIM1 (0.54) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL2424658 0.82 PDE4B (1.00) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL31521577 0.82 PDE4B (1.00) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL2424653 0.82 PDE4B (1.00) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL15421515 0.82 PDE4B (1.00) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL15731907 0.81 IGF1R (0.78) IGF1RPIM1PIM3PIM2PDE4B
SCHEMBL3669823 0.81 IGF1R (0.60) IGF1RPIM1PIM3PIM2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4425628-B2 2010-03-03 JP claimed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP claimed
JP-2005505519-A 2005-02-24 JP claimed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP claimed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US claimed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO claimed
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 US disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 IGF1R 4492/4885PIM1 4421/4885PIM3 4592/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 IGF1R 4492/4885PIM1 4421/4885PIM3 4592/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 IGF1R 4492/4885PIM1 4421/4885PIM3 4592/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 IGF1R 4492/4885PIM1 4421/4885PIM3 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.